MedMira Reports Third Quarter Results FY2026

Executive Summary

• MedMira Inc. reported its financial results for the third quarter of fiscal year 2026 (ended April 30, 2026), showing a significant increase in revenue and gross profit compared to the previous quarter, while narrowing its net loss year-over-year.
• The company advanced the regulatory approval process for its Multiplo® Complete Syphilis test, receiving initial feedback from Health Canada and completing the second phase of clinical trials.
• International expansion efforts are underway, including regulatory submissions in Australia under the Mutual Recognition Agreement and evaluations in selected EMEA markets.

Key Details

• Revenue: $241,189 for Q3 FY2026, compared to $24,503 in Q2 FY2026 and $59,117 in Q3 FY2025.
• Gross Profit: $176,409 for Q3 FY2026, compared to $18,132 in Q2 FY2026 and $43,011 in Q3 FY2025.
• Operating Expenses: $441,218 for Q3 FY2026, compared to $423,180 in Q2 FY2026 and $772,776 in Q3 FY2025.
• Net Loss: $483,660 for Q3 FY2026, compared to a net loss of $657,552 for the same period last year.
• Assets: Decreased by $176,935 between Q2 and Q3 FY2026, primarily due to depreciation expense on corporate assets.
• Liabilities: Increased by $306,725 between Q2 and Q3 FY2026; current liabilities increased by $263,164 due to higher accounts payable and accrued liabilities.
• Loans in Default: Decreased by $9,522 due to currency fluctuations (USD and Swiss Franc); long and short-term debts are currently under negotiation for restructuring.
• Working Capital Deficit: Recorded a deficit of $365,147, an increase of 2% compared to the previous quarter.
• Regulatory Updates: Received initial feedback from Health Canada for the Multiplo® TP/nTP Antibody Test; second phase of clinical trials completed with data to be submitted to support the existing application.
• International Expansion: Initiated regulatory approval processes in Australia under the Mutual Recognition Agreement and is pursuing similar initiatives in selected EMEA markets.

Notable Quotes

• No direct quotes from the CEO or President were included in the provided text.